Trial · NCT06715280
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in mean pulmonary artery pressure (mPAP) | 26 weeks | Change in mean pulmonary artery pressure (mPAP) measured in right heart catheterization at baseline and at week 26. Pulmonary hypertension (PH) is defined as pulmonary artery pressure (PAP) ≥ 25 mmHg. And the normal resting PAP is 8-20 mmHg. |
| Primary | Change in pulmonary vascular resistance (PVR) | 26 weeks | Change in pulmonary vascular resistance (PVR) measured in right heart catheterization at baseline and at week 26. Pulmonary vascular resistance (PVR) is similar to systemic vascular resistance (SVR) except it refers to the arteries that supply blood to the lungs. |
| Secondary | Change in cardiac output (CO) | 26 weeks | Change in cardiac output (CO) measured in right heart catheterization. Cardiac output (CO) is the product of the heart rate (HR), i.e. the number of heartbeats per minute (bpm), and the stroke volume (SV), which is the volume of blood pumped from the left ventricle per beat. |
| Secondary | Change in cardiac index (CI) | 26 weeks | Change in cardiac index (CI) measured in right heart catheterization. The cardiac index (CI) is a hemodynamic measure that represents the cardiac output (CO) of an individual divided by their body surface area (BSA). It is crucial in assessing patients with heart failure and other cardiovascular conditions |
| Secondary | Change in pulmonary artery wedge pressure (PAWP) | 26 weeks | Change in pulmonary artery wedge pressure (PAWP) measured in right heart catheterization. It is the pressure measured by wedging a pulmonary artery catheter with an inflated balloon into a small pulmonary arterial branch |
| Secondary | Change in The World Health Organization (WHO) functional class | 26 weeks | Change in WHO functional class describes how severe a patient's pulmonary hypertension (PH) symptoms. There are four different classes - I is the mildest and IV the most severe form of PH. |
| Secondary | Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) level | 26 weeks | Change in NT-proBNP level which is a protein that's an "ingredient" for making the BNP hormone. Like BNP, your heart makes larger amounts of NT-proBNP when it has to work harder to pump blood. |
| Secondary | Change in walk distance by 6-minutes walk test | 26 weeks | Change in walk distance by 6-minutes walk test which is a sub-maximal exercise test used to assess aerobic capacity and endurance. |
| Secondary | Change in Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL) score | 26 weeks | Change in Pulmonary Embolism Quality of Life Questionnaire score which is a reliable instrument to specifically assess Quality of Life following Pulmonary Embolism, which is helpful in the identification of patients with decreased Quality of Life following acute Pulmonary Embolism. |
| Secondary | Change in REVEAL lite 2 risk score | 26 weeks | Change in REVEAL lite 2 risk score which is quickly calculate patient's risk score and to help determine whether treatment escalation may be needed |
| Secondary | Change in tricuspid regurgitation pressure gradient (TRPG) | 26 weeks | Change in tricuspid regurgitation pressure gradient (TRPG) which reflects the difference in pressure between the right ventricle and right atrium on echocardiogram |
| Secondary | Change in tricuspid annular plane systolic excursion (TAPSE) | 26 weeks | Change in tricuspid annular plane systolic excursion (TAPSE) which a parameter of global RV function which describes apex-to-base shortening on echocardiogram |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06715280/registered